{"id":"mva-bn-half-dose-regimen","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Injection site reaction (erythema, swelling, pain)"},{"rate":"20-40","effect":"Myalgia"},{"rate":"20-35","effect":"Fatigue"},{"rate":"15-30","effect":"Headache"},{"rate":"5-15","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL6068545","moleculeType":"Small molecule","molecularWeight":"570.67"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"MVA-BN is a live, attenuated viral vaccine vector derived from vaccinia virus that has been engineered to express immunogenic proteins from monkeypox virus. The half-dose regimen reduces the vaccine dose while maintaining immunogenicity, potentially improving tolerability and expanding vaccine supply. It works by stimulating both cellular and humoral immune responses against monkeypox antigens.","oneSentence":"MVA-BN is a modified vaccinia Ankara-based vaccine expressing monkeypox antigens that primes the immune system to recognize and respond to monkeypox virus infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:20.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Monkeypox (mpox) prevention in adults at risk of exposure"}]},"trialDetails":[{"nctId":"NCT06844487","phase":"PHASE3","title":"Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-05-29","conditions":"Mpox (Monkeypox), Vaccination, Immunogenicity","enrollment":344}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MVA-BN half-dose regimen","genericName":"MVA-BN half-dose regimen","companyName":"Jean-Pierre Van geertruyden","companyId":"jean-pierre-van-geertruyden","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVA-BN is a modified vaccinia Ankara-based vaccine expressing monkeypox antigens that primes the immune system to recognize and respond to monkeypox virus infection. Used for Monkeypox (mpox) prevention in adults at risk of exposure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}